Biofrontera Inc (BFRI) Stock Price, Quote & News

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatmen...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 245 1325

Website: www.biofrontera-us.com

Address:

120 Presidential Way, Suite 330, Woburn, United States

Bulltrader988 Jul. 31 at 6:26 PM

$BFRI ....👃👀

0 · Reply

Kazeek06 Jul. 29 at 11:21 PM

$BFRI Watching

1 · Reply

ivo98 Jul. 28 at 9:20 AM

$BFRI is allready anticipating on a next split :-)

1 · Reply

Dijon02 Jul. 25 at 10:46 AM

$BFRI

0 · Reply

Bulltrader988 Jul. 24 at 6:30 PM

$BFRI ... Still here and waiting for a big move 👃👀

0 · Reply

GDS100 Jul. 23 at 9:06 PM

$BFRI adding here till the results are out

0 · Reply

Stereo Jul. 23 at 8:36 PM

$BFRI This upcoming clinical trial completion is the big one. We are 2 to 4 months out. https://www.clinicaltrials.gov/study/NCT05080764

1 · Reply

Stereo Jul. 23 at 8:17 PM

$BFRI Slowly but surely

0 · Reply

Jonjon342 Jul. 23 at 8:02 PM

$BFRI

0 · Reply

tushar0077 Jul. 23 at 7:46 PM

$BFRI keep an eye on this one... 👁 👁

0 · Reply

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Jun 11, 2025, 3:00 PM EDT - 7 weeks ago

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Jun 3, 2025, 2:30 PM EDT - 2 months ago

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

May 16, 2025, 3:36 PM EDT - 2 months ago

Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript

May 15, 2025, 5:09 PM EDT - 2 months ago

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

May 15, 2025, 12:17 PM EDT - 2 months ago

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

May 6, 2025, 12:45 PM EDT - 3 months ago

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

May 1, 2025, 2:38 PM EDT - 3 months ago

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Mar 21, 2025, 11:20 AM EDT - 4 months ago

Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript

Mar 21, 2025, 8:00 AM EDT - 4 months ago

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Mar 18, 2025, 9:30 AM EDT - 4 months ago

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Mar 11, 2025, 10:00 AM EDT - 5 months ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Jan 8, 2025, 9:50 AM EST - 7 months ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Dec 23, 2024, 9:30 AM EST - 7 months ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 3, 2024, 11:00 AM EST - 8 months ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 22, 2024, 9:10 AM EST - 9 months ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 14, 2024, 3:02 PM EST - 9 months ago

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 5:15 PM EST - 9 months ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 1, 2024, 11:55 AM EDT - 9 months ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Oct 31, 2024, 10:32 AM EDT - 9 months ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 10 months ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 7, 2024, 8:45 AM EDT - 10 months ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Sep 25, 2024, 10:45 AM EDT - 11 months ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 15, 2024, 1:34 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 9, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

May 16, 2024, 2:44 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:45 PM EDT - 1 year ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 6, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 3, 2024, 8:50 AM EDT - 1 year ago

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Mar 26, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Mar 18, 2024, 12:13 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

Mar 15, 2024, 8:25 PM EDT - 1 year ago

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 15, 2024, 6:10 PM EDT - 1 year ago

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 8, 2024, 9:00 AM EST - 1 year ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Mar 5, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

Feb 23, 2024, 8:40 AM EST - 1 year ago

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Feb 20, 2024, 8:10 AM EST - 1 year ago

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Feb 20, 2024, 8:05 AM EST - 1 year ago

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

Feb 5, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Jan 11, 2024, 4:15 PM EST - 1 year ago

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023

Nov 10, 2023, 1:54 PM EST - 1 year ago

Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:10 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 3, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

Oct 31, 2023, 8:01 AM EDT - 1 year ago

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Oct 5, 2023, 9:00 AM EDT - 1 year ago

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

Bulltrader988 Jul. 31 at 6:26 PM

$BFRI ....👃👀

0 · Reply

Kazeek06 Jul. 29 at 11:21 PM

$BFRI Watching

1 · Reply

ivo98 Jul. 28 at 9:20 AM

$BFRI is allready anticipating on a next split :-)

1 · Reply

Dijon02 Jul. 25 at 10:46 AM

$BFRI

0 · Reply

Bulltrader988 Jul. 24 at 6:30 PM

$BFRI ... Still here and waiting for a big move 👃👀

0 · Reply

GDS100 Jul. 23 at 9:06 PM

$BFRI adding here till the results are out

0 · Reply

Stereo Jul. 23 at 8:36 PM

$BFRI This upcoming clinical trial completion is the big one. We are 2 to 4 months out. https://www.clinicaltrials.gov/study/NCT05080764

1 · Reply

Stereo Jul. 23 at 8:17 PM

$BFRI Slowly but surely

0 · Reply

Jonjon342 Jul. 23 at 8:02 PM

$BFRI

0 · Reply

tushar0077 Jul. 23 at 7:46 PM

$BFRI keep an eye on this one... 👁 👁

0 · Reply

kcarroll92 Jul. 23 at 7:45 PM

$BFRI fresh

0 · Reply

Swedish1 Jul. 23 at 7:40 PM

$BFRI

0 · Reply

ivo98 Jul. 23 at 7:13 PM

$BFRI did I started the hype 🤔🤣

0 · Reply

Whites12 Jul. 23 at 2:27 PM

$BFRI Go to 1.30

0 · Reply

Swedish1 Jul. 23 at 10:49 AM

$BFRI

0 · Reply

rickahuna Jul. 16 at 4:32 PM

$BFRI Biofrontera's Ameluz® patent approved, ensuring market exclusivity through December 2043 for revised propylene glycol-free formulation. BCC and SCC, and .... most profitable: Moderate to severe acne ♦ Phase II ongoing Acne vulgaris treatment approval would be a major development and easily make Ameluz a huge cash cow. I saw Ameluz when it first was displayed at a medical conference and thought it would be in wider use already. These trials should have been started earlier, but if data is supportive, all will be good. (Still, Ameluz is a first line AK treatment) Just have to wait and see. Big Risk but potentially Very Big Reward .

0 · Reply

Ozi_85 Jul. 14 at 6:43 PM

$BFRI I pulled out of this with just a 10% gain...knowing my luck, this will jump upwards of $15 and ill regret leaving it 😭

0 · Reply

Tboonepickem Jul. 10 at 11:47 AM

$BFRI Are we finally starting to wake up?

0 · Reply

Bulltrader988 Jul. 9 at 9:40 PM

$BFRI interesting Form 3 filled.... Biofrontera AG.... "...On June 30, 2025, the Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent the Reporting Person on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes...." 👃👀 https://www.sec.gov/Archives/edgar/data/1712641/000171264125000002/xslF345X02/primary_doc.xml

0 · Reply

Swagg Jul. 9 at 3:17 PM

$BFRI This only needs some volume.

0 · Reply

Stock_Catcher Jul. 9 at 1:58 PM

$BFRI lighter vol

0 · Reply

Dingo2 Jul. 9 at 1:44 PM

$BFRI hmmm - getting a little lift?

0 · Reply

Market Cap	10.65M
Revenue (ttm)	37.32M
Net Income (ttm)	-17.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-47.59%
Debt to Equity Ratio	8.98

Volume	125,800
Avg Vol	191,864
Day's Range	N/A - N/A
Shares Out	10.14M
Stochastic %K	73%
Beta	0.43
Analysts	Strong Sell
Price Target	$6.38